UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2026

Biogen Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-19311 33-0112644
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142

(Address of principal executive offices; Zip Code)

Registrant’s telephone number, including area code: (617) 679-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0005 par value per share BIIB The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07Submission of Matters to a Vote of Security Holders

On June 9, 2026, Biogen Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

1.Stockholders elected ten nominees to the Board of Directors to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:
Nominee Votes For Votes Against Abstentions Broker Non-Votes
Maria C. Freire

103,033,121

18,790,237

84,064

9,359,127

William A. Hawkins

102,135,204

19,683,098

89,120

9,359,127

Susan K. Langer

103,931,406

17,886,544

89,472

9,359,127

Jesus B. Mantas

101,698,187

20,117,077

92,158

9,359,127

Lloyd Minor

121,220,738

594,000

92,684

9,359,127

Menelas Pangalos

121,130,060

682,983

94,379

9,359,127

Monish Patolawala

120,796,249

1,016,057

95,116

9,359,127

Eric K. Rowinsky

93,569,685

28,216,589

121,148

9,359,127

Stephen A. Sherwin

103,025,923

18,788,272

93,227

9,359,127

Christopher A. Viehbacher

121,127,966

688,051

91,405

9,359,127

2.Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:
Votes For Votes Against Abstentions
124,551,887 6,627,086 87,576
3.Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:
Votes For Votes Against Abstentions Broker Non-Votes
114,184,816 7,454,737 267,869

9,359,127

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biogen Inc.
By: /s/ Wendell Taylor
Wendell Taylor
Secretary
Date: June 10, 2026